10d
Zacks Investment Research on MSNMerck Slips 8% in a Month: Should You Buy, Hold or Sell the Stock?Merck MRK stock has declined 7.8% in the past month — in roughly the span after it announced fourth-quarter 2024 results and ...
4d
Zacks.com on MSNMerck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...
CNN on MSN13d
A little-known Chinese company made a drug that beat the world’s biggest-selling medicineAstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group last year to develop cardiovascular medication ...
Silence’s execs will presumably be adjusting their plans to the fact that they can no longer hope for up to $1.3 billion in biobucks to come their way from a deal with Hansoh. The Chinese ...
Also, Viking was seen by some as a potential acquisition target for Merck. However, Merck announced in December 2024 it was licensing Hansoh Pharma's obesity drug HS-10535. This move added a new (and ...
Merck is one of the largest pharmaceutical companies ... HS-10535, with China-based Hansoh Pharma. It signed a similar licensing deal with LaNova Medicines for the development of LM-299, a ...
AstraZeneca signed a $1.92 billion deal with China’s CSPC Pharmaceutical Group last year to develop cardiovascular medication, and Merck has a $2 billion agreement with China’s Hansoh ...
Merck reported adjusted earnings of $1.72 per ... a charge of 23 cents related to M&A deals with LaNova Medicines and Hansoh Pharma. Revenues rose 7% year over year (9% excluding Fx) to $15. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results